UniQuest Pty Limited
https://uniquest.com.au/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From UniQuest Pty Limited
Ultragenyx Data De-Risk Phase III Trial Of Setrusumab
The Mereo-partnered drug is in pivotal development for osteogenesis imperfecta. Ultragenyx also recently reported positive Phase III data for a rare disease gene therapy.
Deal Watch: Lilly Sends European Commercial Rights For Two Migraine Drugs To Organon
Plus deals involving Biocytogen, Neurocrine and Ona, Aeterna Zentaris/Ceapro, Teva/Biolojic Design, Pathos AI/Rain Oncology, Inhibitor Therapeutics/Johns Hopkins and more.
Chinese ADC, RNA Therapy Developers Lead May/June Fundraising
Emerging companies including Bliss Biopharmaceutical, Coherent Biopharma and WestGene Biopharma lifted China biotech funding from May to mid-June.
Finding Cutting-Edge Science Takes A Broad Net, J&J Innovation’s Urban Says
Reflecting on the latest batch of deals, Global Head Robert Urban discusses the progress J&J Innovation has made so far and the next steps as it launches its JLINX incubator.
Company Information
- Industry
- Biotechnology
- Other Names / Subsidiaries
-
- Dendright Pty Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice